| Name | Title | Contact Details |
|---|---|---|
Alim Seit-Nebi |
Chief Technology Officer | Profile |
Lung Therapeutics pursues innovative treatments for underserved, life-threatening lung conditions.
Insmed is a global biopharmaceutical company focused on the needs of patients with rare diseases. Headquartered in Bridgewater, NJ, Insmed is a dynamic and rapidly growing company with a strong pipeline of drug candidates. At Insmed, we are on a mission to transform the lives of patients battling serious rare diseases. We are developing novel, targeted therapies to help serve the critical unmet needs of these patients. In concert with developing therapeutic solutions, we are committed to improving the entire patient experience. “Insmed is a team of talented and motivated professionals who are dedicated to making a difference in the lives of patients with rare diseases, said Will Lewis, president and CEO at Insmed.
Tibotec (tee-bo-tek) Therapeutics was established in March 2003 as a division of Ortho Biotech Products, L.P. Headquartered in Bridgewater, N.J., the organization is dedicated to providing innovative virology therapeutics that help healthcare
Palvella Therapeutics was founded with the single-minded goal of serving individuals suffering from serious rare genetic diseases with no approved treatments.
Evelo Therapeutics is the latest breakthrough microbiome company from Flagship VentureLabs, the innovation foundry of Flagship Ventures.